Mercaptamine ophthalmic - Leadiant Biosciences

Drug Profile

Mercaptamine ophthalmic - Leadiant Biosciences

Alternative Names: Cystaran; Cysteamine; Cysteamine HCl; Cysteamine hydrochloride; Cysteamine ophthalmic solution; Dropcys

Latest Information Update: 06 Mar 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sigma-Tau Pharmaceuticals
  • Developer Leadiant Biosciences; Lucane Pharma
  • Class Antibacterials; Antidotes; Hepatoprotectants; Mercaptoethylamines; Mucolytics; Small molecules
  • Mechanism of Action Glutathione synthase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystinosis
  • New Molecular Entity No

Highest Development Phases

  • Marketed Cystinosis

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 28 Feb 2017 Sigma-Tau Pharmaceuticals is now called Leadiant Biosciences
  • 01 Apr 2016 The Committee for Medicinal Products for Human Use (CHMP) recommends refusal of marketing authorisation for mercaptamine in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top